NewsRx

Search our medical news database

EntreMed, Inc.

EntreMed receives U.S. patent for analogs of anticancer compound

Published in Law and Health Weekly, March 18th, 2006

EntreMed, Inc. (ENMD) announced the issuance of U.S. patent No. 6,995,278 covering analogs of its lead compound, 2-methoxyestradiol (2ME2 or Panzem). Panzem is currently in clinical trials for cancer, as well as in preclinical development for inflammatory disorders.

The patent grants EntreMed composition-of-matter intellectual property protection through 2020 for analogs of 2ME2 in oncology and a broad range of nononcology indications, including inflammatory and immune disorders, rheumatoid arthritis, and other diseases characterized by abnormal cell division (mitosis).

Panzem is a novel anticancer agent, which is part of a next generation of...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook